Abstract The Toxicology Investigators Consortium (ToxIC) Case Registry was established in 2010 by the American College of Medical Toxicology. The Registry includes all medical toxicology consultations performed at participating sites. This report summarizes the Registry data for 2013. A query of the ToxIC Registry was carried out for the dates of January 1 through December 31, 2013. Specific data reviewed for analysis included demographics (age, gender), source of consultation, reasons for consultation, agents involved in toxicological exposures, signs, symptoms and clinical findings, and treatment. A total of 8,598 cases were entered into the Registry in 2013. Females accounted for 49.2 % of cases, males for 47.7 %, and gender was not reported in 3.1 %. The majority of patients (63.4 %) were adults between the ages of 19 and 65 years. There were 93 fatalities (1.1 %). Most referrals for medical toxicology consultation originated from the emergency department (59.7 %) or inpatient services (16.7 %). Exposures to pharmaceutical products (intentional and unintentional) made up 50.0 % of cases. Illicit drug abuse (8.0 %) and adverse drug reactions (ADRs) (4.8 %) were the next most frequent reasons for consultation. Similar to past years, nonopioid analgesics, sedative-hypnotics, and opioids were the most commonly encountered agents. Symptoms or clinical findings were documented in 71.1 % of patients. Of all cases, 54.6 % required some form of medical treatment (antidotes, antivenom, chelation, specific types of supportive care). This report serves as a comprehensive survey of medical toxicology practice within participating institutions. Prior trends continued to apply this year and indicate analgesic (opioid and nonopioid), sedativehypnotic/muscle relaxant agents, illicit drug use, and ADRs continue to be major toxicological problems. Cases requiring medical toxicology consultation in 2013 predominantly involved pharmaceuticals and illicit drugs. Reasons for these drug exposures were diverse and included intentional overdose, unintentional exposure, withdrawal syndromes, and ADRs. Nonopioid analgesics, sedative-hypnotic agents, and opioids remained the most frequently encountered agent classes. While over half of cases required some form of medical treatment, fatalities were uncommon.
Introduction
In 2010, the Toxicology Investigators Consortium (ToxIC) of the American College of Medical Toxicology (ACMT) created a registry intended to provide a tool for clinical toxicology research and toxico-surveillance [1] . Unlike other poisoning databases, the ToxIC Registry prospectively collects information on patients seen in consultation by medical toxicologists as hospital inpatients or in outpatient clinics. These toxicologists enter the patient data directly into the Registry. Since its inception in 2010 with four initial participating institutions, the ToxIC Registry has expanded to include investigators at 38 sites who see patients at 69 separate facilities. The object of this report is to summarize the Registry's 2013 data.
Patients entered from January 1, 2013 through December 31, 2013 are described in this report. This is the fourth annual report for the Registry [2] [3] [4] .
Several sub-registries were developed after the inception of ToxIC. Three were added in 2013 focusing on North American snake bites, prescription drug misuse, and a clinical poisoning severity score. These, in addition to the existing ones on caustic ingestions and lipid resuscitation therapy, bring the total number of sub-registries to five. During 2013, six abstracts based on Registry data were presented at three national and international meetings.
Methods
Participating investigators agree to enter data on all of their medical toxicology consultations into the Registry. Cases are entered on a password-protected, online data collection form. The site is maintained by the ACMT and is overseen by the ToxIC Registry Steering Committee. The Registry is Health Insurance Portability and Accountability Act compliant and does not collect any identifying patient information. Participation in the Registry is compliant with local Institutional Review Board policies and procedures as well as the Western Institutional Review Board.
Collected data include presenting signs, symptoms, clinical course, treatments, patient demographics, location, and the reason for toxicological exposure. The term consultation is used in this report to describe any encounter with the medical toxicologist, including admission to a toxicology inpatient service and consultation on other inpatient units, emergency department, and outpatient clinic visits. The online collection form is formatted to ensure that the data remain organized and easily searchable. There are also areas for free-text entry where providers may describe the case in more detail or offer supplementary information that is not available as a preexisting check box. As part of the Registry's mission of providing a real-time toxico-surveillance tool, a component of the standard data form is a sentinel detection field that signals novel or unusual cases. For this report, a search of the database was performed to identify encounters recorded from January 1, 2013 through December 31, 2013. Additional details collected in the subregistries will be published separately.
In tables describing agent classes, unless otherwise indicated, substances with fewer than five occurrences were not listed as separate items. Exceptions to this practice include the agent comprising a significant fraction of the class or if there was only one agent in the table. Percentages noted in tables of specific agents represent the proportion of those agents within its agent class.
Results
The individual institutions participating in the ToxIC Registry are listed in Table 1 . In 2013, a total of 8,598 cases, representing an increase of 18.3 % over 2012 ( Fig. 1) , were entered.
Demographics
Females comprised 4,234 (49.2 %) cases, compared to 4,100 (47.7 %) males. Gender was not reported in 3.1 % of cases. Fifty-six (1.3 %) were pregnant, 0.6 % of all cases. Adults between the ages of 19 and 65 accounted for a majority (63.4 %) of reported cases. Adolescents (13 to 18 years) were the next most frequent, making up 14.9 %. Additional demographic data are summarized in Table 2 .
Source of Referrals and Primary Reason for Encounter
Hospital emergency departments were the most frequent source of referral, accounting for 5,133 (59.7 %) of Registry cases (Table 3) . Inpatient services and patients transferred directly from other facilities were the next most common source of consultation. There were 384 outpatient referrals, accounting for 4.5 %. As seen in Table 4 , exposures to pharmaceuticals, both intentional and unintentional, were the reason for referral in half of all cases. Drug abuse, encompassing illicit, prescription, and over-the-counter agents, was the next most frequent. Collectively, drug abuse was responsible for 11.7 % of cases. Adverse drug reactions (ADRs), defined in the Registry as undesirable effects of therapeutic drug use, were the reason for 4.8 %.
Agent Classes
A total of 11,279 individual agents were listed in case entries. The distribution of these agents among the 40 different substance classes predefined in the Registry is shown in Table 5 . Exposure to more than one agent was reported in 27.9 % of cases. Nonopioid analgesics, sedative-hypnotic agents including muscle relaxants, and opioids were the most common categories comprising over a third of all reported agents. Overall, exposures to pharmaceutical products including prescription and nonprescription drugs were reported in 80.9 % of cases.
Signs and Symptoms
At least one clinical sign or symptom was reported in 6,116 (71.1 %) cases. These are summarized and organized by clinical syndrome or organ system in Table 6 . Neurological signs or symptoms were described most frequently, with coma or CNS depression found in 26 % of all cases. This finding is consistent with the sedative-hypnotic toxidrome being most common among the syndromes. Agitation and delirium were also common, with each being reported in 9.2 % of cases. Among vital sign abnormalities, significant tachycardia (defined in the Registry as a heart rate of greater than 140 beats per minute) was the most frequent, described in 9.9 % of cases. All other categories of symptoms or findings were documented in less than 7 % of cases.
Fatalities
There were 93 (1.1 %) fatalities (Table 7 ) with 47.3 % being female. Their average age was 46.5 years. Nonopioid analgesics were the agent class most frequently associated with fatalities. At least one analgesic drug was implicated in 22.6 % of the fatalities. Opioids were the second most frequently implicated, comprising 17.2 % of the deaths. Cardiovascular drugs comprised the third most common class in fatal cases (15.1 %).
Individual Agent Classes
Tables 8 through 40 summarize the frequency of specific drugs enumerated by class.
Treatment
Specific treatments were provided to 4,695 (54.6 %) patients. At least one antidote was given to 2,334 (27.1 %) patients and 356 (4.1 %) received more than one, resulting in 2,825 instances of separate antidote administration (Table 41) . Nacetylcysteine accounted for nearly a third (30.5 %) of all antidote administrations. Opioid antagonists (naloxone or nalmefene) and sodium bicarbonate were the next most frequent collectively comprising another 32.2 % of total antidote use. Antivenoms and chelators were used in 1.4 and 0.3 % of cases, respectively (Tables 42 and 43 ). Almost all antivenom treatments (91.8 %) involved polyvalent anti-Crotalidae Fab fragments. Over half of chelation treatments (53.6 %) utilized DMSA, with an additional 21.4 % of cases involving deferoxamine. Supportive care with pharmacologic agents was provided in 1,681 (19.6 %) cases (Tables 44 and 45 ). A total of 2,089 treatments were documented, and 336 (3.9 %) patients received more than one type of treatment. Benzodiazepine administration accounted for over half (56.0 %) of (Tables 46 and 47) . Only 388 (4.5 %) patients received some form of decontamination, with 28 (0.3 %) receiving more than one type. Oral activated 
Adverse Drug Reactions
ADRs were the reason for medical toxicology consultation in 580 (4.8 %) of the Registry cases. A total of 177 drugs were implicated at least once. Table 48 lists the 15 most frequently encountered drugs associated with ADRs (≥10 occurrences), along with their percentage of the total number of ADR cases. More than one drug was involved in 129 (22 %) of these cases.
Limitations
Reporting bias is a potential limitation of any database dependent on spontaneous reporting. However, all participating sites agree, as a condition of participation, that all of their cases will be entered into the Registry thus minimizing such bias. Incomplete data entry is a limitation. As seen in Tables 2, 3 , and 4, some case data were missing. This is an area of ongoing quality improvement for the Registry. When such data are missing, it is typically less than 5 % of the total cases for any given field, making it unlikely to significantly impact the results and trends. However, this problem was most notable in the fatal cases (Table 7) , where a specific exposure was not documented a Includes lisdexamfetamine, cathinone, phentermine, tetrahydrozoline, α-pyrrolidinopentiophenone (α-PVP), epinephrine, 2C-T-7, ephedrine, phendimetrazine, phenylpropanolamine, propylhexedrine, and methylone WMD weapons of mass destruction in a substantial fraction of entries. Another limitation is that other than fatality, there is no mechanism to determine the relative severity of outcome. In fatal cases where toxic exposure is responsible for clinical symptoms or findings, it is likely that death is attributable to poisoning. However, the current data collection methods do not allow for distinguishing whether a secondary, nontoxic etiology is responsible for death. a Percentages are out of the total number of treatments administered (2,089); 3.9 % of registry cases received more than one form of treatment. The ToxIC Registry is not population based and has a specific ascertainment bias, which is present by design. The key inclusion criterion for entry into the Registry is the consultation by a medical toxicologist. Thus, Registry cases represent patients for whom there was a concern for significant toxicity. Cases of no, or mild, toxicity are likely to be underrepresented.
Discussion
This report of the ToxIC Registry serves as a comprehensive overview of cases involving medical toxicology consultations. The number of cases ( Fig. 1) and number of participating institutions have grown steadily since the Registry's inception in 2010.
For the most part, the patterns seen in this report are similar to the trends seen in prior years [3] . The pattern of ADRs deserves further discussion. Adverse drug reactions are a considerable patient safety issue. Overall, ADRs ranked as the fourth most common reason for consultation. It is interesting that of the most common drugs associated with ADRs, only three, acetaminophen, oxycodone, and fentanyl, belong to the top three agent classes found in Table 5 . Rather ADRs were dominated by antidepressants, antipsychotics, and anticonvulsants. The reason for this pattern is not clear. However, the medication types presented in Table 48 may indicate a disproportionate representation of psychiatric patients in ADR consultations. Nevertheless, these medications have a significant intrinsic potential for toxicity. Since the ADRs represented in this Registry are likely to be serious, future studies should be focused on evaluating their causes and clinical syndromes in more detail.
There have been a number of upgrades to the Registry in 2014 which should be evident in next year's annual report. Because most of the cases involve intentional pharmaceutical ingestions, we are evaluating the reasons for taking the medication in more detail. This includes an assessment of intent to determine if the medication was taken for therapeutic purposes, for attempts at self-harm, or for other reasons, such as to generate a pleasurable effect. Additional information about intent is being collected within each of these categories. Furthermore, this year, we are also beginning to obtain ethnic and racial data to refine the demographic profile for patients with the various kinds of toxicologic disease enumerated in this report.
Another factor of considerable interest to medical toxicologists involves the decision to terminate life support. This decision is especially complicated because of the difficulties in assessing brain death or neurological function when central nervous system-active medications are present, particularly in the high concentrations that are often found in these patients. In 2014, we began collecting additional information regarding the decision to terminate life support, and these data should be reflected in next year's report.
Conclusions
Cases requiring medical toxicology consultation in 2013 predominantly involved pharmaceuticals and illicit drugs. Reasons for these drug exposures were diverse and included intentional overdose, unintentional exposure, withdrawal syndromes, and ADRs. Nonopioid analgesics, sedative-hypnotic agents, and opioids remained the most frequently encountered agent classes. While over half of cases required some form of medical treatment, fatalities were uncommon. 
